Detalles de la búsqueda
1.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
N Engl J Med
; 388(23): 2145-2158, 2023 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36972026
2.
Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
Br J Cancer
; 130(10): 1716-1724, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38658783
3.
Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets.
Gynecol Oncol
; 184: 111-116, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38301309
4.
A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.
Gynecol Oncol
; 188: 13-21, 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38861917
5.
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
Int J Gynecol Cancer
; 2024 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38627035
6.
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
Gynecol Oncol
; 169: 164-171, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36333181
7.
Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation.
Gynecol Oncol
; 177: 132-141, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37683549
8.
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol
; 170: 300-308, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36758420
9.
TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
Gynecol Oncol
; 178: 44-53, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37748270
10.
The Genomic Landscape of Vulvar Squamous Cell Carcinoma.
Int J Gynecol Pathol
; 42(5): 515-522, 2023 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37131274
11.
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Future Oncol
; 19(23): 1577-1591, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37334673
12.
Systematic mapping review of guidelines for BRCA1/2 genetic testing globally: investigating geographic and regional disparities in health equity for women and families at risk for hereditary ovarian cancer.
Int J Gynecol Cancer
; 33(2): 250-256, 2023 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36368709
13.
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.
Int J Gynecol Cancer
; 33(11): 1733-1742, 2023 11 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37931976
14.
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Int J Gynecol Cancer
; 33(4): 562-570, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564099
15.
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Int J Gynecol Cancer
; 33(9): 1458-1463, 2023 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37666539
16.
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
N Engl J Med
; 381(20): 1929-1939, 2019 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31722153
17.
Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
Gynecol Oncol
; 167(2): 306-313, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36229265
18.
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
Gynecol Oncol
; 167(3): 429-435, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36244828
19.
HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.
Gynecol Oncol
; 167(2): 289-294, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36114027
20.
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
Gynecol Oncol
; 166(3): 410-416, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35835612